Ste Virbac News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

26.04.23	Virbac : Public release of Virbac Annual Report at 31 December 2022 (ESEF format) (GlobeNewswire)
17.04.23	VIRBAC: Slight decline in first-quarter revenue primarily due to a base effect as well as a context of market slowdown (GlobeNewswire)
06.04.23	Virbac : Declaration of the number of shares and voting rights 03/2023 (GlobeNewswire)
23.03.23	Virbac : Public release of the Year-End Consolidated Accounts at 31 December 2022 (GlobeNewswire)
23.03.23	VIRBAC: 2022 current operating income on the rise at +8.3%, reflecting the momentum of our business over the year in a slowing market (GlobeNewswire)
03.03.23	Virbac : Declaration of the number of shares and voting rights 02/2023 (GlobeNewswire)
28.02.23	Virbac : Declaration of the number of shares and voting rights 01/2023 (GlobeNewswire)
18.10.22	VIRBAC: Revenue growth at end of September at +7.7% at comparable exchange rates and perimeter (+12.7% at actual rates (GlobeNewswire)
15.09.22	Virbac: increase in operating income in the first half of 2022 reflecting the dynamism of our business (GlobeNewswire)
19.07.22	VIRBAC: growth in revenue in the first half of 2022 of +12.0% at comparable exchange rates (+16.4% at real rates), driven by good performance in all areas (GlobeNewswire)
14.04.22	Virbac : Very strong growth in revenue in the first quarter of 2022 of +16.2% at comparable exchange rates (+19.3% at real rates), driven by good performance in all areas (GlobeNewswire)
22.03.22	VIRBAC: 2021 operating profit from ordinary activities showed very strong growth, reflecting the excellent dynamism of our business in a rapidly growing market (GlobeNewswire)
19.01.22	VIRBAC: Exceptional growth in annual revenue of +18.4% at comparable exchange rates and scope (+14.9% at constant rates and real scope), driven by remarkable performance in a very buoyant market (GlobeNewswire)
05.11.21	Virbac: Aquaculture - Virbac completes the acquisition of Centrovet (GlobeNewswire)
18.10.21	Virbac: excellent revenue growth of 21.2% at the end of September at comparable exchange rates and scope (+16.4% at constant rates and real scope), driven by a very solid third-quarter performance aga (GlobeNewswire)
15.09.21	Virbac: Significant increase in operating profit from ordinary activities for the first half of 2021 due to the sound market performance and dynamism of our business (GlobeNewswire)
13.09.21	Virbac : Aquaculture : Virbac strengthens its position in Centrovet (GlobeNewswire)
20.07.21	Virbac: Exceptional increase in revenue in the first half of 2021, with +21.3% at comparable exchange rates and scope (+14% at constant exchange rates and actual scope), driven by very solid performan (GlobeNewswire)
05.07.21	Virbac: driven by very solid performance in all areas and a very dynamic market, we are raising our outlook for 2021 (GlobeNewswire)
15.04.21	Virbac: very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven by very solid performance in all areas (GlobeNewswire)
17.03.21	Virbac: 2020 current operating income showed strong growth (+37.6% at constant rates and scope), reflecting the excellent evolution of revenue (+5.7% at constant rates and scope) and a sharp decrease (GlobeNewswire)
17.03.21	Virbac 2020 Year-end consolidated accounts (GlobeNewswire)
19.01.21	VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) (GlobeNewswire)
14.10.20	VIRBAC: Revenue grew +6.8% at constant exchange rates and scope at the end of September 2020 (+5.6% at constant rates) thanks to solid third quarter performance (GlobeNewswire)
13.10.20	Virbac will change its governance at its shareholders' meeting on December 15 (GlobeNewswire)
16.09.20	Virbac : Half-yearly financial report 2020 (GlobeNewswire)
16.09.20	VIRBAC: Operating profit from ordinary activities up sharply for the first half of 2020 reflecting revenue resiliency and strong expenditure restraint during the Covid-19 crisis (GlobeNewswire)
20.07.20	Virbac: Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year (GlobeNewswire)
02.07.20	Virbac completes divestment of U.S. Rights to SENTINEL® brands to MSD Animal Health (GlobeNewswire)
13.05.20	Virbac to divest U.S. Rights to SENTINEL® brands to MSD Animal Health (GlobeNewswire)
30.04.20	Virbac Annual Report 2019 (GlobeNewswire)
15.04.20	Virbac: 2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying (GlobeNewswire)
16.03.20	Virbac: 2019 operating profit from ordinary activities on the rise (GlobeNewswire)
16.01.20	Virbac: 2019 annual revenue shows strong growth of +6.6% at constant exchange rates (GlobeNewswire)
20.12.19	Virbac : the Group raises the 2019 annual outlook (GlobeNewswire)
15.11.19	Virbac : quarterly financial information as of September 30, 2019 (GlobeNewswire)
11.10.19	Virbac : solid +8.4% growth in revenue at constant exchange rates at the end of September, 2019 (GlobeNewswire)
16.09.19	Virbac : Half-yearly financial report 2019 (GlobeNewswire)
16.09.19	Virbac: operating profit on the rise in the first half of 2019 (GlobeNewswire)
16.07.19	Virbac : 2019 first half-year revenue grew by +6.6% at constant exchange rates (GlobeNewswire)
11.04.19	Virbac : 2019 first quarter revenue rose by +10.9% at comparable exchange rates (GlobeNewswire)
18.03.19	Virbac: 2018 operating profit from ordinary activities grew by 13.4% (GlobeNewswire)
17.01.19	Virbac : 2018 annual revenue grew by +4.5% at constant exchange rates (GlobeNewswire)
11.10.18	Virbac : revenue grew by +5.5% at constant exchange rates at the end of September 2018 (GlobeNewswire)
17.07.18	Virbac : Revenue grew by +4.3% at constant exchange rates in the second quarter of 2018 (GlobeNewswire)
12.04.18	Virbac : 2018 first quarter revenue rose by +3.3% at comparable exchange rates (GlobeNewswire)
14.03.18	Virbac : operating profit from ordinary activities 2017 comparable to 2016 (GlobeNewswire)
16.01.18	Virbac : annual sales comparable to 2016 at constant exchange rates after strong fourth-quarter growth (GlobeNewswire)
22.11.17	Virbac : Aquaculture: Virbac postpones its option to buy Centrovet for three years (GlobeNewswire)
12.10.17	Virbac: quarterly sales affected by distributor destocking in the United States (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ste Virbac SA

Aktien Top/Flop

Meistgelesene Nachrichten